City of Hope Medical Center

Serial Clinical and Biomarker Monitoring during Graft-Versus-Host Disease Treatment Identifies Distinct Risk Strata Including an Ultra-Low Risk Group (2025) Katsivelos N, Spyrou N, Weber D, Vasova I, Ayuk F, Choe H, Hogan W, et al. Journal article Polygenic score distribution differences across European ancestry populations: implications for breast cancer risk prediction (2024) Yiangou K, Mavaddat N, Dennis J, Zanti M, Wang Q, Bolla MK, Abubakar M, et al. Journal article The MAGIC algorithm probability predicts treatment response and long-term outcomes to second-line therapy for acute GVHD (2024) DeFilipp Z, Kim HT, Spyrou N, Katsivelos N, Kowalyk S, Eng G, Kasikis S, et al. Journal article Amphiregulin, ST2, and REG3α biomarker risk algorithms as predictors of nonrelapse mortality in patients with acute GVHD (2024) Etra A, Jurdi NE, Katsivelos N, Kwon D, Gergoudis S, Morales G, Spyrou N, et al. Journal article Recurrent Wnt Pathway and ARID1A Alterations in Sinonasal Olfactory Carcinoma (2024) Rooper LM, Agaimy A, Bell D, Gagan J, Gallia GL, Jo VY, Lewis JS, et al. Journal article Novel MAGIC composite scores using both clinical symptoms and biomarkers best predict treatment outcomes of acute GVHD (2024) Akahoshi Y, Spyrou N, Weber D, Aguayo-Hiraldo P, Ayuk F, Chanswangphuwana C, Choe HK, et al. Journal article Flares of acute graft-versus-host disease: a Mount Sinai Acute GVHD International Consortium analysis. (2024) Akahoshi Y, Spyrou N, Hoepting M, Aguayo-Hiraldo P, Ayuk F, Chanswangphuwana C, Choe HK, et al. Journal article A Day 14 Endpoint for Acute GVHD Clinical Trials (2024) Spyrou N, Akahoshi Y, Kowalyk S, Morales G, Beheshti R, Aguayo-Hiraldo P, Al Malki MM, et al. Journal article Differences in Acute Graft-Versus-Host Disease (GVHD) Severity and Its Outcomes Between Black and White Patients (2024) Rios CA, Qayed M, Etra AM, Reshef R, Newcomb R, Yuhasz N, Hexner EO, et al. Journal article A phase 2 open-label study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (EMPOWER-CSCC-1): Final long-term analysis of groups 1, 2, and 3, and primary analysis of fixed-dose treatment group 6 (2024) Hughes BG, Guminski A, Bowyer S, Migden MR, Schmults CD, Khushalani NI, Chang ALS, et al. Journal article